<html>
<head>
    <meta http-equiv="content-type" content="text/html; charset=utf-8" />
    <meta name="description" content="" />
    <meta name="keywords" content="" />
    <!--[if lte IE 8]><script src="css/ie/html5shiv.js"></script><![endif]-->
    <script src="/js/jquery.min.js"></script>
    <script src="/js/jquery.dropotron.min.js"></script>
    <script src="/js/skel.min.js"></script>
    <script src="/js/skel-layers.min.js"></script>
    <script src="/js/init.js"></script>
    <script src="/js/lightbox.js"></script>
    <link rel="stylesheet" href="/css/pygment.css"/>
    <noscript>
        <link rel="stylesheet" href="/css/skel.css" />
        <link rel="stylesheet" href="/css/style.css" />
        <link rel="stylesheet" href="/css/style-noscript.css" />
        <link href="/css/lightbox.css" rel="stylesheet"/>
    </noscript>
    <script src="//cdnjs.cloudflare.com/ajax/libs/modernizr/2.6.2/modernizr.min.js"></script>
    <!-- <link href="//netdna.bootstrapcdn.com/font-awesome/4.1.0/css/font-awesome.min.css" rel="stylesheet"> -->
    <link rel="stylesheet" href="//cdn.materialdesignicons.com/1.3.41/css/materialdesignicons.min.css">
    <link  href="http://fonts.googleapis.com/css?family=Anonymous+Pro:regular,italic,bold,bolditalic" rel="stylesheet" type="text/css" >
    <!--[if lte IE 8]><link rel="stylesheet" href="/css/ie/v8.css" /><![endif]-->
    <!--[if lte IE 9]><link rel="stylesheet" href="/css/ie/v9.css" /><![endif]-->
    <style>
    body, #skel-layers-wrapper {
    background: #CFF4EF;}
    </style>

    <!-- Favicon for all devices and sizes -->
    <link rel="apple-touch-icon-precomposed" sizes="57x57" href="/apple-touch-icon-57x57.png" />
    <link rel="apple-touch-icon-precomposed" sizes="114x114" href="/apple-touch-icon-114x114.png" />
    <link rel="apple-touch-icon-precomposed" sizes="72x72" href="/apple-touch-icon-72x72.png" />
    <link rel="apple-touch-icon-precomposed" sizes="144x144" href="/apple-touch-icon-144x144.png" />
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/apple-touch-icon-60x60.png" />
    <link rel="apple-touch-icon-precomposed" sizes="120x120" href="/apple-touch-icon-120x120.png" />
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/apple-touch-icon-76x76.png" />
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/apple-touch-icon-152x152.png" />
    <link rel="icon" type="image/png" href="/favicon-196x196.png" sizes="196x196" />
    <link rel="icon" type="image/png" href="/favicon-96x96.png" sizes="96x96" />
    <link rel="icon" type="image/png" href="/favicon-32x32.png" sizes="32x32" />
    <link rel="icon" type="image/png" href="/favicon-16x16.png" sizes="16x16" />
    <link rel="icon" type="image/png" href="/favicon-128.png" sizes="128x128" />
    <meta name="application-name" content="&nbsp;"/>
    <meta name="msapplication-TileColor" content="#FFFFFF" />
    <meta name="msapplication-TileImage" content="/mstile-144x144.png" />
    <meta name="msapplication-square70x70logo" content="/mstile-70x70.png" />
    <meta name="msapplication-square150x150logo" content="/mstile-150x150.png" />
    <meta name="msapplication-wide310x150logo" content="/mstile-310x150.png" />
    <meta name="msapplication-square310x310logo" content="/mstile-310x310.png" />


    <title>Tomas Bos | Yeo Lab </title>
        <meta charset="utf-8" />
        <meta name="viewport" content="width=device-width">
</head>

<body class=" loading">



    <!-- Header -->
    <header id="header" >
        <h1 class="logo">
            <a href="..">Yeo Lab</a>
        </h1>
        <nav id="nav">
            <ul>
                <!-- <li class="current"><a href="index.html">Welcome</a></li> -->
                    <li><a href="/research/">Research</a></li>
                    <li><a href="/papers/">Papers</a></li>
                    <li><a href="/funding/">Funding</a></li>
                    <li><a href="/software/">Software</a></li>
                    <li><a href="/links/">Links</a></li>
                <li><a href="/people" class="button special">People</a></li>
            </ul>
        </nav>
    </header>

<style>
.image:before{
  background-image: None;
}
img.clown {
  height: 100%;
  /*Border-radius 50% makes it a circle*/
  border-radius: 50%;
  margin-top: -49px;
}
</style>
<!-- Main -->
<article id="main">

  <header class="special container">
    <span class="icon"><img src="/images/people/tomas_bos.jpg" class="clown"></span>
    <h2>Tomas&nbsp;Bos</h2>
    <!-- add page sub title here -->
    <p>Post-Doctoral Fellow

      <!-- If there's a position suffix
      (e.g. Bioinformatics Analyst "I, (Ph.D.))"", add it -->

      <!-- If they are alumni, specify -->
<br>

      <!-- Add program/department affiliation, if applicable -->
      Cellular and Molecular Medicine<br>

    <!-- Add their fellowship, if applicable -->
    Tbos@ucsd.edu</p>
  </header>

  <!-- One -->
    <section class="wrapper style4 container">

      <!-- Content -->
        <div class="content">
          <section>
            <p><h2>Degrees</h2>
<p>PhD in Medical Sciences, Vrije Universiteit Brussel, 2010<br>
<span class="caps">M.S.</span> in Molecular Biology and Biotechnology, Vrije Universiteit Brussel, 2004<br>
<span class="caps">M.S.</span> in Biotechnical Engineering, De Nayer Instituut, 2003<br>
B.S Pharmaceutical and Biological Techniques, Erasmushogeschool Brussel, 2001<br></p>
<h2>Summary</h2>
<p>Tomas Bos received his PhD in Medical Sciences from the Vrije Universiteit Brussel, Belgium in 2010. Dr. Bos investigated during his PhD novel ways to deliver lentiviral vectors more efficiently to cancer cells. Another focus during his PhD was the explodingfield of epigenetics. He identified novel epigenetic layers in the regulation of the pro-apoptotic Bim protein in Multiple Myeloma. More specific, he showed that the <span class="caps">IGF1</span> growth factor is directly involved in modifying the epigenetic signature of both the Bim and the FoxO3A promoter. His wide interest in science resulted in publications in very diverse fields ranging from diabetes to in vivo small animal imaging and in the Emmanuel Vander Schueren Award. Before joining the Yeo lab, he stayed a fewmonths at the Salk Institute in the department of Regulatory Biology to study the role of <span class="caps">CTCF</span> in breast cancer. Dr. Bos is now studying the role of <span class="caps">RNA</span>-binding proteins (RBPs) in alternative splicing of pre-mRNA. Other projects he is involved in are the use of genomic engineering tools (<span class="caps">TALEN</span> and <span class="caps">CRIPR</span>/<span class="caps">CAS</span>) to engineer recombinant cell lines, the <span class="caps">ENCODE</span> project studying the sequence specificity of RBPs in <span class="caps">RNA</span> and the family of <span class="caps">ADAR</span> proteins Dr. Bos is funded by the Belgian American Education Foundation (<span class="caps">BAEF</span>) and is a Hoover Foundation Brussels&nbsp;Fellow.</p>
<h2>Publications</h2>
<ul>
<li>
<p>Batra R, Stark <span class="caps">TJ</span>, Clark E, Belzile <span class="caps">JP</span>, Wheeler <span class="caps">EC</span>, Yee <span class="caps">BA</span>, Huang H, Gelboin-Burkhart C, Huelga <span class="caps">SC</span>, Aigner S, Roberts <span class="caps">BT</span>, <strong>Bos <span class="caps">TJ</span></strong>, Sathe S, Donohue <span class="caps">JP</span>, Rigo F, Ares M Jr, Spector <span class="caps">DH</span>, Yeo <span class="caps">GW</span>. <span class="caps">RNA</span>-binding protein <span class="caps">CPEB1</span> remodels host and viral <span class="caps">RNA</span> landscapes. Nat Struct Mol Biol. 2016&nbsp;Dec;23(12):1101-1110. </p>
</li>
<li>
<p>Goethals <span class="caps">LR</span>, <strong>Bos <span class="caps">TJ</span></strong>, Baeyens L, De Geeter F, Devoogdt N, Lahoutte T. Camelid reporter gene imaging: a generic method for in vivo cell tracking. <span class="caps">EJNMMI</span> Res. 2014;4(1):32.&nbsp;doi:10.1186/s13550-014-0032-8.</p>
</li>
<li>
<p>Dmitriev P, Petrov A, Ansseau E, et al. The Krüppel-like factor 15 as a molecular link between myogenic factors and a chromosome 4q transcriptional enhancer implicated in facioscapulohumeral dystrophy. J Biol Chem. 2011;286(52):44620-44631.&nbsp;doi:10.1074/jbc.M111.254052.</p>
</li>
<li>
<p>Emeagi <span class="caps">PU</span>, Van Lint S, Goyvaerts C, et al. Proinflammatory characteristics of <span class="caps">SMAC</span>/<span class="caps">DIABLO</span>-induced cell death in antitumor therapy. Cancer Res. 2012;72(6):1342-1352. doi:10.1158/0008-5472.<span class="caps">CAN</span>-11-2400.</p>
</li>
<li>
<p>De Bruyne E, <strong>Bos <span class="caps">TJ</span></strong>, Asosingh K, et al. Epigenetic silencing of the tetraspanin <span class="caps">CD9</span> during disease progression in multiple myeloma cells and correlation with survival. Clin Cancer Res. 2008;14(10):2918-2926. doi:10.1158/1078-0432.<span class="caps">CCR</span>-07-4489.</p>
</li>
<li>
<p><strong>Bos <span class="caps">TJ</span></strong>, De Bruyne E, Van Lint S, Heirman C, Vanderkerken K. Large double copy vectors are functional but show a size-dependent decline in transduction efficiency. J Biotechnol. 2010;150(1):37-40.&nbsp;doi:10.1016/j.jbiotec.2010.07.010.</p>
</li>
<li>
<p>Caers J, Hose D, Kuipers I, et al. Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma. Haematologica. 2010;95(1):163-167.&nbsp;doi:10.3324/haematol.2009.006411.</p>
</li>
<li>
<p>Baeyens L, Bonné S, <strong>Bos <span class="caps">TJ</span></strong>, et al. Notch signaling as gatekeeper of rat acinar-to-beta-cell conversion in vitro. Gastroenterology. 2009;136(5):1750–60.e13.&nbsp;doi:10.1053/j.gastro.2009.01.047.</p>
</li>
<li>
<p>De Bruyne E, <strong>Bos <span class="caps">TJ</span></strong>, Schuit F, et al. <span class="caps">IGF</span>-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood. 2010;115(12):2430-2440.&nbsp;doi:10.1182/blood-2009-07-232801.</p>
</li>
<li>
<p>Keyaerts M, Remory I, Caveliers V, et al. Inhibition of firefly luciferase by general anesthetics: effect on in vitro and in vivo bioluminescence imaging. Hamblin M, ed. PLoS <span class="caps">ONE</span>. 2012;7(1):e30061.&nbsp;doi:10.1371/journal.pone.0030061.</p>
</li>
<li>
<p><strong>Bos <span class="caps">TJ</span></strong>, De Bruyne E, Heirman C, Vanderkerken K. In search of the most suitable lentiviral shRNA system. Curr Gene Ther.&nbsp;2009;9(3):192-211.</p>
</li>
<li>
<p>Bonehill A, Tuyaerts S, Van Nuffel <span class="caps">AMT</span>, et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with <span class="caps">CD40L</span>, <span class="caps">CD70</span> and constitutively active <span class="caps">TLR4</span> encoding mRNA. Mol Ther. 2008;16(6):1170-1180.&nbsp;doi:10.1038/mt.2008.77.</p>
</li>
<li>
<p>Keyaerts M, Verschueren J, <strong>Bos <span class="caps">TJ</span></strong>, et al. Dynamic bioluminescence imaging for quantitative tumour burden assessment using <span class="caps">IV</span> or <span class="caps">IP</span> administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging. 2008;35(5):999-1007.&nbsp;doi:10.1007/s00259-007-0664-2.</p>
</li>
</ul></p>
          </section>
        </div>

    </section>

  </article>


<!-- Footer -->

<style>
#footer .mdi{
  font-size: 4em;
}
</style>

<footer id="footer">

    <ul class="icons">
        <li>
          <a href="http://github.com/yeolab" class="mdi mdi-github-circle"><span class="label"></span></a>
        </li>
        <li>
          <a href="http://twitter.com/yeo_lab" class="mdi mdi-twitter-circle"><span class="label"></span></a>
        </li>
    </ul>

    <span class="copyright">&copy; Yeo Lab. All rights reserved. Design: <a href="http://html5up.net">HTML5 UP</a>.</span>

</footer>
</body>
</html>